netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 12 of 12


Details
LDL Link Added : MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases : https://www.gov.uk/drug-safety-update/cdk4-slas
06/07/2023 11:09:37
(rpaylor )
LDL Link Added : NICE TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy : https://www.nice.org.uk/guidance/ta836
15/11/2022 16:58:35
(DavidS )
UPD sitematrix Changed from 0 to
15/11/2022 16:58:16
(DavidS )
UPD FurtherInformation Changed from
15/11/2022 16:58:16
(DavidS )
UPD Palbociclib (Ibrance®) NICE TA836
15/11/2022 16:58:16
(DavidS )
UPD Published from Draft Mode
21/05/2020 10:24:25
(DavidS )
UPD Palbociclib (Ibrance®) updated
21/05/2020 10:23:53
(DavidS )
UPD Palbociclib (Ibrance®) NICE TA619
20/05/2020 15:32:48
(DavidS )
LDL Link Added : NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer : https://www.nice.org.uk/guidance/ta619
20/05/2020 15:31:42
(DavidS )
UPD Published from Draft Mode
09/05/2018 10:55:12
(LoweryM )
LDL Link Added : NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer : https://www.nice.org.uk/guidance/ta495
27/04/2018 11:44:23
(DavidS )
ADD Palbociclib (Ibrance®) Approved at APC (April 2018) following positive NICE TA495
27/04/2018 11:33:08
(DavidS )

 

 
netFormulary